All Cholesterol articles
-
BusinessBreaking the silence of RNA interference drugs
A wave of treatments is set to follow the first approval of an RNAi therapy
-
Opinion
The projects drug companies wish they’d never started
Failures are common in drug research, but some are bigger than others
-
Opinion
Making enough of a difference
What if the needle in the drug development haystack ends up being too small to be useful?
-
-
Business
Merck resolves Vytorin case for $688m
Investors say the company knew about Enhance trial failure but withheld information
-
-
Business
HDL drug class struggling after latest flop
The failure of another ‘good’ cholesterol-raising drug and a new genetic study casts shadow over HDL hypothesis
-
Business
PCSK9 inhibitors against cholesterol problems perform well
Sanofi has reported Phase II data for a new drug candidate for lowering cholesterol levels in patients already taking statins
